StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Wednesday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.27 on Wednesday. The stock’s 50-day moving average price is $0.36 and its 200-day moving average price is $1.00. The company has a market capitalization of $3.35 million, a P/E ratio of -0.04 and a beta of 0.49. Oragenics has a 52 week low of $0.25 and a 52 week high of $7.74.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent filing with the Securities and Exchange Commission (SEC). 18.71% of the stock is owned by institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.